Live Breaking News & Updates on Ricardod parrondo

Stay informed with the latest breaking news from Ricardod parrondo on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ricardod parrondo and stay connected to the pulse of your community

Dr Parrondo on the Use of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

Ricardo D. Parrondo, MD, discusses the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

Ricardod-parrondo , Mayo-clinic , D , Cartitude-4-trial , Cilta-cel- , Lenalidomide-refractory-multiple-myeloma ,

Dr Parrondo on the RedirecTT-1 Trial of Teclistamab Plus Talquetamab in Multiple Myeloma

Ricardo D. Parrondo, MD, discusses the phase 1b/2 RedirecTT-1 of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Ricardod-parrondo , Mayo-clinic , Onclive-tv , Myeloma , Teclistamab-and-talquetamab , Hase-1b-2-redirectt-1- ,

Dr Parrondo on the Investigation of GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma

Ricardo D. Parrondo, MD, discusses the exploration of the non-BCMA CAR T-cell target GPRC5D in multiple myeloma.

Ricardod-parrondo , Mayo-clinic , Onclive-tv , Myeloma , Car-t , Gprc5d ,

Research Developments Provide Clarity and Raise Further Questions in Myeloma, Myelofibrosis, DLBCL, and MDS

Sikander Ailawadhi, MD, discusses characteristics of myelofibrosis that influence decisions between JAK inhibitors, highlights differences between bispecific antibodies to consider when managing diffuse large B-cell lymphoma, and more.

Mayo-clinic-in-rochester , Minnesota , United-states , Jacksonville , Florida , Muhamad-alhaj-moustafa , Sikander-ailawadhi , Naseema-gangat , Talha-badar , Ricardod-parrondo , Institutional-perspectives

Further Research Is Needed to Maximize Efficacy of Current Treatment Options in Hematologic Malignancies

Ricardo D. Parrondo, MD, highlights the current use of covalent BTK inhibitors in chronic lymphocytic leukemia, potential roles for the non-covalent BTK inhibitor pirtobrutinib, and the importance of future research on time-limited treatment options for patients with newly diagnosed chronic lymphocytic leukemia.

Minnesota , United-states , Mayo-clinic-in-rochester , Hemants-murthy , Candidoe-rivera , Muhamad-alhaj-moustafa , Ricardod-parrondo , National-comprehensive-cancer-network , Science-summit , Mayo-clinic , D , S

Dr Parrondo on the Current Treatment Landscape of MCL

Ricardo D. Parrondo, MD, discusses the current treatment landscape of mantle cell lymphoma and highlights ongoing areas of investigation in other hematologic malignancies.

Ricardod-parrondo , Mayo-clinic , Mantle-cell-lymphoma , Onclive-tv , Mmayo-clinic , Mcl ,

Dr Parrondo on the Clinical Benefit of Momolotinib on Anemia in Myelofibrosis

Ricardo D. Parrondo, MD, discusses the clinical benefit seen with momelotinib in anemic myelofibrosis, and where it fits into the current treatment paradigm in this disease landscape.

Ricardod-parrondo , Mayo-clinic , Jak-inhibitors-in-myelofibrosis , Momelotinib-ojjaara- , Ruxolitinib , Momentum , Simplify-1 ,